A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATION

1999165 citationsJournal Article

Authors

Short term enlimomab induction therapy after renal transplantation did not reduce the rate of acute rejection or DGF.

Good health and well-being

Published in: Transplantation

Volume 67, Issue 5, pp. 729-736

Field-Weighted Citation Impact: 6.62